|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
207,851,000 |
Market
Cap: |
11.75(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$31.86 - $59.82 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Catalent is a holding company. Through its subsidiaries, Co. has two operating and reporting segments: Biologics and Pharma and Consumer Health. The Biologics segment provides development and manufacturing for biologic proteins; cell, gene, and other nucleic acid therapies; plasmid DNA; induced pluripotent stem cells; and vaccines. The Pharma and Consumer Health segment comprises Co.'s capabilities for oral solids, softgel formulations, Zydis® fast-dissolve technologies, and gummy, soft chew, and lozenge dosage forms; formulation, development, and manufacturing platforms for oral, nasal, inhaled, and topical dose forms; and clinical trial development and supply services.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
1,000 |
1,000 |
Total Buy Value |
$0 |
$0 |
$49,980 |
$49,980 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
387 |
387 |
11,063 |
116,582 |
Total Sell Value |
$21,749 |
$21,749 |
$512,581 |
$11,151,362 |
Total People Sold |
1 |
1 |
12 |
18 |
Total Sell Transactions |
1 |
1 |
25 |
69 |
End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Fasman Steven L |
EVP & Chief Admin Officer |
|
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,788 |
56,509 |
|
- |
|
Fasman Steven L |
EVP & Chief Admin Officer |
|
2022-07-26 |
4 |
S |
$106.90 |
$272,167 |
D/D |
(2,546) |
53,721 |
|
55% |
|
Castellano Thomas P |
SVP, Chief Financial Officer |
|
2022-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
2,323 |
17,374 |
|
- |
|
Castellano Thomas P |
SVP, Chief Financial Officer |
|
2022-07-26 |
4 |
S |
$106.90 |
$37,094 |
D/D |
(347) |
15,051 |
|
55% |
|
Gennadios Aristippos |
Group Pres. Pharma & Consumer |
|
2022-07-01 |
4 |
A |
$107.02 |
$2,000,097 |
D/D |
18,689 |
80,187 |
|
- |
|
Arnold Jonathan |
SVP & Chief Commercial Ofcr |
|
2022-07-01 |
4 |
A |
$107.02 |
$300,084 |
D/D |
2,804 |
48,792 |
|
- |
|
Fasman Steven L |
SVP & General Counsel |
|
2022-06-10 |
4 |
AS |
$106.77 |
$535,352 |
D/D |
(5,000) |
56,178 |
|
-36% |
|
Gargiulo Mario |
SVP Global Ops Large Molecule |
|
2022-06-10 |
4 |
S |
$106.59 |
$12,578 |
D/D |
(118) |
4,640 |
|
36% |
|
Zippelius Peter |
Director |
|
2022-02-06 |
4 |
S |
$102.65 |
$49,999,994 |
I/I |
(487,092) |
4,330,462 |
|
2% |
|
Hopson Ricky |
VP, Chief Accounting Officer |
|
2022-01-31 |
4 |
AS |
$103.39 |
$240,382 |
D/D |
(2,325) |
17,073 |
|
6% |
|
Whitlow Ricci S |
President, CSS |
|
2022-01-21 |
4 |
AS |
$102.37 |
$18,836 |
D/D |
(184) |
2,923 |
|
2% |
|
Flynn Karen |
Chief Commercial Officer |
|
2022-01-10 |
4 |
AS |
$116.64 |
$288,334 |
D/D |
(2,472) |
33,223 |
|
-16% |
|
Fasman Steven L |
SVP & General Counsel |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,017 |
61,178 |
|
- |
|
Grippo Michael J |
SVP, Strategy & Corp. Dev. |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,017 |
16,519 |
|
- |
|
Pravda Ricardo |
SVP & Chief HR Officer |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,017 |
15,764 |
|
- |
|
Arnold Jonathan |
Pres. Oral & Specialty Deliv. |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,017 |
45,988 |
|
- |
|
Gennadios Aristippos |
President Softgel & Oral Tech |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,017 |
61,498 |
|
- |
|
Gunther Scott |
SVP, Quality & Reg. Affairs |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,017 |
22,079 |
|
- |
|
Lucier Gregory T |
Director |
|
2021-11-23 |
4 |
S |
$126.98 |
$645,407 |
I/I |
(5,068) |
0 |
|
14% |
|
Arnold Jonathan |
Pres. Oral & Specialty Deliv. |
|
2021-11-01 |
4 |
AS |
$140.02 |
$1,494,293 |
D/D |
(10,672) |
41,971 |
|
-31% |
|
Arnold Jonathan |
Pres. Oral & Specialty Deliv. |
|
2021-11-01 |
4 |
OE |
$36.02 |
$338,421 |
D/D |
7,559 |
52,643 |
|
- |
|
Gargiulo Mario |
SVP Global Ops Large MoleculeO |
|
2021-10-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
4,758 |
|
-29% |
|
Carletti Lorenzo |
SVP Global Ops Small MoleculeO |
|
2021-10-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,580 |
|
-29% |
|
Castellano Thomas P |
SVP, Chief Financial Officer |
|
2021-10-20 |
4 |
AS |
$134.00 |
$309,138 |
D/D |
(2,307) |
15,398 |
|
-23% |
|
Arnold Jonathan |
Pres. Oral & Specialty Deliv. |
|
2021-10-14 |
4 |
AS |
$129.41 |
$214,950 |
D/D |
(1,661) |
45,084 |
|
-21% |
|
821 Records found
|
|
Page 9 of 33 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|